We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Drug Stocks to Watch for Earnings on Nov 4; REGN & More
Read MoreHide Full Article
The bulk of the Q3 earnings season is over, with 364 S&P 500 members (as of Nov 2) – accounting for 72.6% of the index’s total market capitalization – having already reported results, according to the latest Earnings Outlook.
While total earnings for these index members were up 1.6% from the year-ago quarter, revenues were also up 1.6% year over year. The beat ratio was 72.3% for earnings and 54.7% for revenues.
Notably, the ongoing reporting cycle is on track to be the first quarter of positive earnings growth after five consecutive quarters of earnings decline for the S&P 500 index. However, though the third-quarter reporting cycle saw numerous positive surprises and stability in current-quarter (Q4 2016) estimates in the beginning, these two attributes have started losing ground this week. Positive surprises, particularly on the revenue side, have become harder to come by and Q4 estimates are moving down.
This change was reflected in the results of pharmaceutical companies as well. Though quite a few of the large-cap pharma companies posted better-than-expected third-quarter results last week, three large pharma companies that have reported so far this week – Allergan plc’s , Gilead Sciences Inc. (GILD - Free Report) and Pfizer Inc. (PFE - Free Report) – announced softer-than-expected Q3 results. While Allergan and Pfizer missed estimates for both earnings and sales, Gilead managed to beat sales expectations marginally but missed earnings estimates.
Two more companies from the healthcare sector are set to report their third-quarter results on Nov 4. Let's see how things are shaping up for their respective announcements.
Regeneron posted a positive surprise of 21.97% last reported. The company’s performance has been mixed so far. In the last four quarters, it surpassed earnings estimates on two occasions and missed the same twice. Overall, the company has recorded an average negative earnings surprise of 2.04%.
Regeneron’s key growth driver, Eylea, should continue to perform well in the third quarter of 2016 and contribute meaningfully to the top line. Apart from Eylea, investor focus will remain on the performance of the PCSK9 inhibitor, Praluent. (Read More: Regeneron Q3 Earnings: Will the Stock Surprise?).
The Zacks Consensus Estimate for the quarter is pegged at $2.27 per share. The company has a Zacks Rank #3 (Hold) and an Earnings ESP of 0.00%. Please check our Earnings ESP Filter that enables you find stocks that are expected to come out with earnings surprises.
Lion Biotechnologies, Inc.
Last quarter, the company delivered a negative earnings surprise of 21.05%. Lion Biotechnologies had a mixed track record over the last four quarters. The company surpassed expectations twice, missed once and delivered in-line results in the other quarter, with the average positive earnings surprise being 9.52%.
This week, Zacks researchers have named 7 other stocks that look to break out even sooner than today's Bull of the Day. You can see these time-sensitive tickers free, and access additional trades that are not available to the public. Simply click here>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Drug Stocks to Watch for Earnings on Nov 4; REGN & More
The bulk of the Q3 earnings season is over, with 364 S&P 500 members (as of Nov 2) – accounting for 72.6% of the index’s total market capitalization – having already reported results, according to the latest Earnings Outlook.
While total earnings for these index members were up 1.6% from the year-ago quarter, revenues were also up 1.6% year over year. The beat ratio was 72.3% for earnings and 54.7% for revenues.
Notably, the ongoing reporting cycle is on track to be the first quarter of positive earnings growth after five consecutive quarters of earnings decline for the S&P 500 index. However, though the third-quarter reporting cycle saw numerous positive surprises and stability in current-quarter (Q4 2016) estimates in the beginning, these two attributes have started losing ground this week. Positive surprises, particularly on the revenue side, have become harder to come by and Q4 estimates are moving down.
This change was reflected in the results of pharmaceutical companies as well. Though quite a few of the large-cap pharma companies posted better-than-expected third-quarter results last week, three large pharma companies that have reported so far this week – Allergan plc’s , Gilead Sciences Inc. (GILD - Free Report) and Pfizer Inc. (PFE - Free Report) – announced softer-than-expected Q3 results. While Allergan and Pfizer missed estimates for both earnings and sales, Gilead managed to beat sales expectations marginally but missed earnings estimates.
Two more companies from the healthcare sector are set to report their third-quarter results on Nov 4. Let's see how things are shaping up for their respective announcements.
Regeneron Pharmaceuticals, Inc. (REGN - Free Report)
Regeneron posted a positive surprise of 21.97% last reported. The company’s performance has been mixed so far. In the last four quarters, it surpassed earnings estimates on two occasions and missed the same twice. Overall, the company has recorded an average negative earnings surprise of 2.04%.
REGENERON PHARM Price and EPS Surprise
REGENERON PHARM Price and EPS Surprise | REGENERON PHARM Quote
Regeneron’s key growth driver, Eylea, should continue to perform well in the third quarter of 2016 and contribute meaningfully to the top line. Apart from Eylea, investor focus will remain on the performance of the PCSK9 inhibitor, Praluent. (Read More: Regeneron Q3 Earnings: Will the Stock Surprise?).
The Zacks Consensus Estimate for the quarter is pegged at $2.27 per share. The company has a Zacks Rank #3 (Hold) and an Earnings ESP of 0.00%. Please check our Earnings ESP Filter that enables you find stocks that are expected to come out with earnings surprises.
Lion Biotechnologies, Inc.
Last quarter, the company delivered a negative earnings surprise of 21.05%. Lion Biotechnologies had a mixed track record over the last four quarters. The company surpassed expectations twice, missed once and delivered in-line results in the other quarter, with the average positive earnings surprise being 9.52%.
LION BIOTECH Price and EPS Surprise
LION BIOTECH Price and EPS Surprise | LION BIOTECH Quote
The Zacks Consensus Estimate for the quarter is pegged at a loss of 18 cents per share. The company has an Earnings ESP of 0.00% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Confidential from Zacks
This week, Zacks researchers have named 7 other stocks that look to break out even sooner than today's Bull of the Day. You can see these time-sensitive tickers free, and access additional trades that are not available to the public. Simply click here>>